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Abstract 
Background: Cisplatin is the main chemotherapeutic drug for the treatment of cervical cancers, however resistance 
to cisplatin is increasingly common and therefore has limited the efficacy and use of this drug in the clinic. Dose‑
dependent toxicity poses an additional challenge since patients suffer long‑term and often permanent side‑effects 
after treatment. Bcl‑2 up‑regulation has been implicated in the resistance to cisplatin in a variety of cancer cell lines, 
however its role in cervical cancer is confounding.
Methods: A low, non‑cytotoxic concentration of cisplatin was used in the treatment of HeLa and CaSki cells. Bcl‑2 
expression was determined through Western blotting and immunocytochemistry before and after treatment with 
cisplatin. To assess the reliance of the cervical cancer cells on Bcl‑2 in the presence of cisplatin, Bcl‑2 knock‑down was 
achieved through RNA interference, where after apoptosis was assessed through PARP cleavage (Western blotting), 
Caspase activity (Caspase‑Glo©) and PI inclusion analysis (Flow cytometry). Finally, pre‑malignant and malignant cervi‑
cal tissue was analysed for the presence of Bcl‑2 through Western blotting and immunofluorescence.
Results: Cervical cancer cells upregulate Bcl‑2 when treated with a non‑cytotoxic concentration of cisplatin, which 
when silenced, effectively enhanced cisplatin sensitivity, and therefore significantly induced apoptosis. Analysis of the 
expression profile of Bcl‑2 in cervical tissue revealed its up‑regulation in cervical carcinoma, which agrees with results 
obtained from the in vitro data.
Conclusions: Our data strongly suggest that utilising a lower dose of cisplatin is feasible when combined with Bcl‑2 
silencing as an adjuvant treatment, thereby improving both the dose‑dependent toxicity, as well as cervical cancer 
resistance.
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Background
It has been over 40 years since the clinical development 
of cis-diaminedichloroplatinum (II) (cisplatin). It has 
been considered as one of the most effective anticancer 
drugs against cervical cancer in neoadjuvant and salvage 
treatment [1]. Despite this success, resistance to cisplatin 
is increasingly common and often culminates in chemo-
therapeutic failure. It is suggested that cisplatin resist-
ance, i.e. failure of cancer cells to undergo apoptosis, may 
be due to a disruption in the normal apoptotic response. 
Increases in cisplatin dosage as a means of circumvent-
ing this resistance has proven impractical since patients 
experience dose-dependent toxicity and long-term dam-
age such as nephro- [2, 3] and ototoxicity [4–6], which 
further decreases the quality of life [7, 8]. It is therefore 
necessary to address both the issues of cisplatin dos-
age, as well as possible mechanisms of resistance in cis-
platin treated cells. This may provide new avenues for 
chemotherapy and adjuvant treatments that would not 
only favour the use of lower concentrations of cisplatin, 
thereby limiting the chemotherapeutic side effects, but 
also lessen the potential for chemoresistance.
Open Access
*Correspondence:  ginal@sun.ac.za 
1 Department of Physiological Sciences, Stellenbosch University, c/o 
Merriman and Bosman road, Stellenbosch, South Africa
Full list of author information is available at the end of the article
Page 2 of 8Leisching et al. J Transl Med  (2015) 13:328 
A systematic survey and meta-analysis of the tran-
scriptional profiles of a variety of cancers indicated that 
the dysregulation of Bcl-2 is a key distinguishing fac-
tor between normal and cancer cells [9]; moreover, its 
increased expression has been correlated with increased 
resistance of a variety of cancers to chemotherapy drugs, 
including cisplatin [10, 11]. Evidence documenting the 
expression of Bcl-2 in cervical cancers is confounding, 
and the role of Bcl-2 under stressful conditions, such as 
chemotherapy treatment in cervical cancer cells remains 
poorly understood. It is therefore necessary to dissect the 
role of this anti-apoptotic protein in cisplatin resistance 
in cervical cancer.
Macroautophagy (hereafter referred to as autophagy) 
is in the majority of cases, considered to serve as a 
pro-survival mechanism, and is up-regulated under 
conditions such as nutrient depletion, hypoxia and 
chemotherapy treatment [12–14]. Apoptosis and 
autophagy share regulatory mechanisms [15] which play 
important roles, not only under normal physiological 
conditions, but also in disease states such as cancer. The 
interaction between Bcl-2 and Beclin-1 proteins is an 
important point of convergence between the apoptotic 
and autophagic pathways. The importance of this inter-
action is underlined by the fact that Beclin-1 is a tumour 
suppressor protein and that inhibition of its function 
by Bcl-2 contributes to the oncogenic potential of Bcl-
2. Its expression often occurs in the absence of Beclin-1 
in malignant cells, therefore ratio analysis of Beclin-1 
and Bcl-2 expression as means of detecting the role of 
autophagy under conditions of apoptosis may have ther-
apeutic value, such that it may be indicative of chemo-
therapeutic success of a treatment.
In the present study we address the issue of cisplatin 
dose-dependent toxicity by using a non-toxic concentra-
tion of the drug on two cervical cancer cell lines through-
out. With this in mind, we aimed to (1) evaluate the basal 
levels of Bcl-2 and Beclin-1 in HeLa and CaSki cell lines, 
(2) silence Bcl-2 as a means of defining its role during 
cisplatin treatment, and finally analyse pre-malignant 
low-grade squamous intraepithelial lesions (LSILs), high-
grade squamous intraepithelial lesions (HSILs), as well as 
malignant cervical tissue for the presence of Bcl-2 under 
basal conditions in order to evaluate its possible role 
in vivo during the progression of cervical cancer and vali-
date the in vitro results.
Methods
Cell culture lines
HeLa and CaSki cells were purchased from Highveld Bio-
logical (Johannesburg, South Africa) and grown in Dul-
becco’s Modified Eagles Medium (DMEM) supplemented 
with 10 % foetal bovine serum (FBS) (Gibco. Ltd) and 1 % 
penicillin/streptomycin (P/S) (Sigma-Aldrich, Johannes-
burg, South Africa). Cells were grown at 37  °C and 5 % 
CO2 under humidified conditions and passaged upon 
reaching 70–80 % confluency.
Cisplatin treatment
Cisplatin (Sigma-Aldrich, Johannesburg, South Africa) 
was prepared before each treatment period by dissolving 
the powder in 0.9  % NaCl solution to obtain a 0.001  M 
stock solution. It was then added to sub-confluent cells 
to reach final working concentration of 15 µM and incu-
bated for a period of 24  h. Cisplatin dose–response 
curves and non-toxic validation of the above mentioned 
working concentration is described in previous work 
published by our group [16].
Immunocytochemistry
HeLa and CaSki cells were grown on coverslips in six-
well plates (250,000 cells/well). Following the treatment 
period, the medium was removed and cells were washed 
once with PBS. Cells were fixed and permeabilised with 
ice-cold methanol and acetone (1:1) and left to incubate 
at 4  °C for 10  min. The fixative was then removed and 
coverslips were allowed to air-dry for a further 20  min 
where after they were rinsed twice with PBS. Non-spe-
cific binding was prevented by incubating cells with 10 % 
donkey serum for 1  h at RT. After this time period, the 
donkey serum was blotted off and Beclin-1 and Bcl-2 pri-
mary antibodies (Cell Signaling, MA, USA) diluted in 1 % 
bovine serum albumin (BSA, 1:50) were added to cells 
and allowed to incubate overnight at 4 °C. Cells were then 
rinsed three times with PBS and allowed to incubate with 
the appropriate secondary antibody (FITC donkey anti-
rabbit and TxRed goat anti-rabbit, Cell Signaling, MA, 
USA) for 1 h at RT. 10 min before the completion of incu-
bation, Hoechst 33342 (1:200) was additionally added for 
the remainder of the incubation period. Next, cells were 
rinsed and the coverslips were mounted on glass slides 
with DAKO fluorescent mounting medium (DAKO Inc., 
CA, USA). Slides were kept at −20 °C until analysis.
Western blotting and immunofluorescence
Cells were lysed with RIPA buffer and whole protein 
extracts were analysed through Western blotting [17] and 
then incubated with the following primary antibodies 
(1:1000 dilution): Bcl-2, Beclin-1, cleaved PARP, LC-3II, 
p62 and β-actin (Cell Signaling, MA, USA). For immuno-
fluorescence, a primary antibody recognising Bcl-2 (Cell 
Signaling, MA, USA) and a secondary antibody conju-
gated to a fluorophore (FITC donkey anti-rabbit, Cell 
Signaling, MA, USA) were used. Bcl-2 expression was 
assessed in all paraffin-embeded cervical tissue and rep-
resentative images were acquired.
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siRNA transfections
Bcl-2 and control/scrambled siRNA were purchased 
from Cell Signaling Technologies (Beverly, MA, USA) 
and supplied as a 10  µM stock solution. The relevant 
proteins were silenced through reverse transfection. 
All transfections were performed using FuGENE6 
(Roche, Johannesburg, South Africa) according to the 
manufacturers instructions. Cells were then incubated 
for 48 h before continuing with treatments and analy-
ses. Silencing was confirmed through Western blot-
ting to detect changes in total amount of the targeted 
proteins.
Caspase 3/7 activity assay
The Caspase-Glo® assay was purchased from Promega 
(Southampton, UK) and was performed according to the 
manufacturer’s instructions.
Flow cytometry: propidium iodide staining
Cells were grown in T25 flasks at a seeding density of 
700,000 cells/flask. After the treatment period, 2  ml 
Tryple-Xpress trypsin (Gibco) was added to each flask 
for 3–4 min until all cells had detached. The cell sus-
pension was then added to 15  ml Falcon tubes and 
centrifuged at 6000×g for 3  min. The supernatant 
was removed and the pellet washed with 0.1  M PBS. 
The cells were centrifuged again at the same specifi-
cations and the supernatant was removed as before. 
PI (Sigma-Aldrich, South Africa) was added to the 
unfixed cells to obtain a final concentration of 1 mg/
ml, incubated for 10  min and analysed on the flow 
cytometer (BD FACSAria I). A minimum of 10,000 
events were collected and analysed using a 488  nm 
laser and 610LP, 616/23BP emission filters. PI inclu-
sion signified loss in membrane integrity and cell 
death. Values were represented as a percentage of the 
control.
Patients and specimen collection
The study protocol has been approved by the 
Research Ethics Committee of Stellenbosch Univer-
sity. Tissue collection was in accordance with the 
ethical standards of the responsible committee on 
human experimentation and with the Helsinki Decla-
ration of 1975, as revised in 1983 (reference number: 
N09/02/045). Biopsies were collected from patients 
undergoing routine colposcopy screenings and hys-
terectomies at Tygerberg Hospital, Tygerberg, West-
ern Cape. Samples were rinsed with PBS, placed in 
cryovials and stored individually in liquid nitrogen 
until further use. A total of 10 non-cancerous, 29 
LSILs, 33 HSILs and 13 carcinoma biopsies were col-
lected for analysis.
Results
Bcl‑2 protein expression levels increase after cisplatin 
treatment in HeLa and CaSki cells
Bcl-2 and Beclin-1 protein expression levels were ana-
lysed before (NT) and after (T) treatment with a non-
toxic concentration of cisplatin for a period of 24  h 
(Fig.  1a). Following treatment with cisplatin, Bcl-2 pro-
tein levels increased significantly in HeLa cells. The addi-
tion of cisplatin (T) induced a significant increase in 
Beclin-1 and Bcl-2 protein levels in CaSki cells. Immuno-
cytochemistry of both cell lines under treatment condi-
tions confirm Western blotting data since treatment with 
cisplatin increases the fluorescent signal of Bcl-2 in both 
Hela and CaSki cells (Fig. 1b).
Bcl‑2 silencing increases intracellular Beclin‑1 protein 
levels in HeLa and CaSki cells
Silencing of Bcl-2 was performed in order to assess 
whether Bcl-2 modulates Beclin-1 expression under con-
ditions of stress, such as during cisplatin treatment. Bcl-2 
silencing was confirmed through Western blotting in 
both HeLa and CaSki cells (Fig.  2a, b). Beclin-1 protein 
levels increased significantly in both groups where Bcl-2 
was silenced. The Beclin-1/Bcl-2 ratio was then assessed 
after silencing of Bcl-2 in HeLa and CaSki cells in order 
to determine whether a shift toward autophagic cell 
death has occurred, since Bcl-2 exerts an inhibitory effect 
on Beclin-1(Fig.  2c). The ratio increased significantly in 
both cell lines which is indicative of an autophagy domi-
nant state within the cell.
Bcl‑2 silencing improves cytotoxicity of cisplatin 
and induces apoptosis in cervical cancer cells
Effector caspase activity, cleaved PARP and cell mem-
brane integrity was analysed as a markers of apoptosis 
and cell death. Silencing of Bcl-2 significantly increased 
cisplatin-induced caspase activation in HeLa and CaSki 
cells (Fig.  3a, c). Equally, the silencing of Bcl-2 signifi-
cantly increased cisplatin-induced PARP cleavage in 
these cells (Fig. 3b, d). The combination of Bcl-2 silencing 
and cisplatin treatment significantly increased the num-
ber of cells positive for PI staining as observed by flow 
cytometry (Fig. 3e). We also observed that Bcl-2 silenc-
ing alone and in combination with cisplatin decreases 
p62 protein expression and increases LC3-II expression 
(Fig. 3f ), thus increasing autophagy.
Bcl‑2 protein expression is increased in cancerous cervical 
tissue
Bcl-2 expression was significantly increased in cervi-
cal carcinoma tissue in comparison to normal tissue, 
LSIL tissue and HSIL tissue (Fig. 4a). Fluorescent micro-
graphs displayed an increase in Bcl-2 expression levels in 
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carcinoma tissue exhibiting 95 % positivity in comparison 
to the control tissue (1 % positivity), LSILs (0 % positiv-
ity) and HSILs (2 % positivity) (Fig. 4b). All positive sam-
ples stained moderately to strongly with Bcl-2.
Discussion
Cisplatin has been widely used to treat solid tumours and 
much success has been achieved from the use of this drug 
in the treatment of head and neck, ovarian, testicular, 
Fig. 1 Analysis of Beclin‑1 and Bcl‑2 protein levels in non‑ treated (NT) and treated (T) HeLa and CaSki cells. a Bcl‑2 and Beclin‑1 protein levels 
in HeLa and CaSki cells were analysed for changes in expression after the addition of 15 μM cisplatin for a period of 24 h. *p < 0.05, **p < 0.01, 
***p < 0.001, n = 3. Analyzed by one‑way ANOVA with Bonferonni post hoc test. b Representative immunofluorescent images of HeLa and CaSki 
cells depicting expression of Bcl‑2 and Beclin‑1 under basal conditions (NT) and in response to cisplatin treatment (T). Blue Hoechst 33342, green 
Bcl‑2 and red Beclin‑1. Scale bar 20 μm, n = 3
Fig. 2 Silencing of Bcl‑2 in HeLa and CaSki cells and resulting expression levels of Beclin‑1. a Silencing of Bcl‑2 confirmed through Western blotting. 
Beclin‑1 protein expression in HeLa cells, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. b Silencing of Bcl‑2 confirmed through Western blotting. Beclin‑1 
protein expression in CaSki cells, *p < 0.05 vs. cisplatin, n = 3. c Ratios were determined according to densitometric analysis of Beclin‑1 and Bcl‑2. 
*p < 0.05 and **p < 0.01, n = 3. Sc. Seq. scrambled sequence (control), AU arbitrary units
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small-cell lung cancer and cervical cancers. The success 
of cisplatin treatment is limited due to its dose-limiting 
toxicity and the resulting, and often permanent side-
effects. Equally challenging is the tendency of cancer 
cells to acquire resistance to cisplatin treatment. There 
is therefore a need for effective treatment options which 
utilise lower doses of cisplatin that are able to maintain 
cytotoxicity and address the issue of resistance.
Bcl-2 expression has been implicated in the resistance 
of various cancers to chemotherapy treatment, but evi-
dence of its role in cervical cancer remains unclear. We 
therefore aimed to dissect the role of this oncogenic pro-
tein in two cervical cancer cell lines and in pre-malignant 
and malignant cervical tissue. Bcl-2 and Beclin-1 protein 
expression levels were analysed in HeLa and CaSki cells 
under control conditions (NT), as well as after a 24  h 
treatment period with a non-cytotoxic concentration of 
cisplatin (T) (Fig. 1a, b). Cisplatin treatment significantly 
increased Bcl-2 protein levels in both cervical cancer cell 
lines which was confirmed through immunocytochemis-
try. It is important to note that the cervical cancer cells 
were viable and had not undergone apoptosis at this 
point. We hypothesise that the upregulation of Bcl-2 that 
is observed may be responsible for the observed survival.
The upregulation of Bcl-2 in the presence of cisplatin 
prompted further analysis in order to elucidate its role in 
cervical cancer survival and its potential interaction with 
Beclin-1. Since Bcl-2 is known to associate with Beclin-1, 
an interaction that serves as a rheostat between apopto-
sis and autophagy induction, it was necessary to dissect 
whether this association was significant under treat-
ment conditions. Silencing of Bcl-2 upregulated Beclin-1 
expression in both cervical cancer cell lines. This obser-
vation is in accordance with a study that showed Bcl-2 
silenced MCF-7 breast cancer cells increased Beclin-1 
expression, and after 72  h resulted in autophagic cell 
death [18]. The Beclin-1/Bcl-2 ratio increased signifi-
cantly in both cell lines with and without the treatment of 
cisplatin. Interpretation of these results allow a distinc-
tion to be made between autophagy acting as a survival 
mechanism and autophagy serving as a mechanism of 
cell death. Beclin-1 expression is required to be elevated 
for the latter to occur [19], which was observed in our 
model.
Fig. 3 The effect of Bcl‑2 silencing on apoptosis during cisplatin treatment in HeLa (a and b) and CaSki (c and d) cells. a Caspase ‑3/‑7 activity, 
**p < 0.01 vs. sc. seq. #p < 0.01 vs. cisplatin and $p < 0.01 vs. Bcl‑2 siRNA, n = 4. b PARP cleavage levels, **p < 0.01 vs. sc. seq., #p < 0.001 vs. cisplatin 
and $p < 0.01 vs. Bcl‑2 siRNA, n = 3. c Caspase‑3/‑7, *p < 0.05 vs. sc.seq. and #p < 0.05 vs. cisplatin, n = 3. d PARP cleavage, **p < 0.01 vs. sc.seq., 
#p < 0.01 vs. cisplatin and $p < 0.01 vs. Bcl‑2 siRNA, n = 3. e PI inclusion (Flow cytometry), PI positive: quadrant A, PI negative: quadrant B *p < 0.05 
vs. Cont., Cispl. and Bcl‑2 siRNA, n = 3. f Western blot detecting p62 and LC‑3 II in HeLa and CaSki cells. Sc. seq. scrambled sequence (control), AU 
arbitrary units
Page 6 of 8Leisching et al. J Transl Med  (2015) 13:328 
Apoptosis occurred in both cell lines after Bcl-2 was 
silenced. Analysis of apoptotic death markers suggests a 
role of Bcl-2 as a mechanism which delays the onset of 
apoptosis, thereby conferring resistance to cisplatin treat-
ment. More importantly however, is the observation that 
the cytotoxicity of cisplatin improved greatly. Both HeLa 
and CaSki cells displayed increased caspase -3/-7 activ-
ity in response to the combination of Bcl-2 silencing and 
cisplatin treatment (Fig. 3a, c). Equally indicative of cell 
death induction was a significant increase in PARP cleav-
age in both cell lines (Fig. 3b, d). Here we show that a pre-
viously non-cytotoxic concentration of cisplatin becomes 
toxic to cervical cancer cells and provides conceptual evi-
dence to suggest that lower dosages of cisplatin may be a 
viable approach to treatment when combined with Bcl-2 
silencing.
The Beclin-1/Bcl-2 ratio after silencing (Fig. 2c), as well 
as various cell death (Fig. 3a–e) and autophagy markers 
(Fig.  3. F) indicates that cell death with autophagy [20, 
21] may be occurring in this in vitro model, as the pres-
ence of apoptosis and autophagy is evident. Our findings 
agree with others in that the silencing of Bcl-2 improved 
sensitivity to cisplatin treatment in bladder cancer cells 
[22], melanoma cells [23], ovarian cancer cells [24], non-
small lung cancer cells [25] and lung adenocarcinoma 
cells [26]. It is important to note that the above studies 
utilised concentrations of cisplatin which induced 50  % 
cell death or more. Here we use a concentration of cispl-
atin which does not induce cell death when administered 
as a single agent. This approach simultaneously addresses 
the challenge of cisplatin toxicity and chemotherapy 
resistance.
To confirm the relevance of the in  vitro data, basal 
levels of Bcl-2 in cervical tissue was analysed. Analysis 
of cervical pre-malignant and malignant tissue revealed 
that Bcl-2 protein expression was significantly increased 
in cervical carcinoma tissue samples (Fig. 4a, b) and sug-
gests that the malignant state requires such an altera-
tion in order to maintain the malignant phenotype. An 
increase in Bcl-2 protein expression as demonstrated in 
this study is in accordance with the results of Dimitraka-
kis and colleagues where it was shown that Bcl-2 pro-
tein expression is directly related to the grade of cervical 
intraepithelial neoplasia [27]. This is however in contrast 
Fig. 4 The Bcl‑2 expression profile in normal, low‑grade and high‑grade squamous intraepithelial lesions and cervical carcinoma tissue of the 
cervix. a Representative Western blot, *p < 0.05, **p < 0.01, ***p < 0.001. Statistical analysis: ANOVA and Bonferroni correction. All results expressed 
as mean ± SEM, normal (n = 4), LSIL (n = 6), HSIL (n = 8) and cervical carcinoma (n = 5). b Representative fluorescent micrographs of Bcl‑2 expres‑
sion profiles in normal, LSIL, HSIL and cervical carcinoma, scale bar 20 μm. LSIL low‑grade cervical intraepithelial lesions, HSIL high‑grade squamous 
intraepithelial lesions, CA carcinoma
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to results in another study where it was demonstrated 
that Bcl-2 protein expression in neoplastic cervical tissue 
is significantly decreased in comparison to the normal 
cervical tissue [28].
Conclusions
In summary, we have demonstrated that in cervi-
cal cancer cells, Bcl-2 is up-regulated as a potential 
means of providing resistance against cisplatin treat-
ment. Silencing of Bcl-2 is able to greatly improve 
cisplatin sensitivity in both cell lines, particularly in 
aggressive CaSki cells. Therefore, the in vitro, as well 
as the ex  vivo data strongly suggest that Bcl-2 is a 
promising therapeutic target for the treatment of cer-
vical cancer. Here we show that it is possible to utilise 
lower doses of cisplatin while addressing cervical can-
cer resistance.
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